This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.
Altes A, Lopez R, Martino R, Martinez C, Cabezudo E, Munoz L et al. Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders. Bone Marrow Transplant 2000; 26: 127–132.
Corso A, Caberlon S, Pagnucco G, Klersy C, Zappasodi P, Alessandrino EP et al. Blood stem cell collections in multiple myeloma: definition of a scoring system. Bone Marrow Transplant 2000; 26: 283–286.
Hosing C, Saliba RM, Ahlawat S, Korbling M, Kebriaei P, Alousi A et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009; 84: 335–337.
Kuittinen T, Nousiainen T, Halonen P, Mahlamaki E, Jantunen E . Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907–912.
Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.
Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331–338.
Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009; 43: 909–917.
Acknowledgements
The development of this manuscript was supported by Sanofi Oncology (formerly Genzyme Corporation). We would like to thank Julie Kern, PhD, and Purvi D Mody, PhD, for editorial support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
IM has served as consultant and advisor for and has received research funding from Genzyme. PS has received research funding from Genzyme. He has also served as advisor for and received honoraria from Genzyme, Millennium and Otsuka. PG is employed by Sanofi Oncology (formerly Genzyme Corporation), and GC was previously employed by Genzyme Corporation. The other authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Micallef, I., Jacobsen, E., Shaughnessy, P. et al. G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT. Bone Marrow Transplant 48, 303–304 (2013). https://doi.org/10.1038/bmt.2012.125
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.125